News
-
Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study In Support Of HemaXellerate™ Cell Therapy
11/19/2012
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate™ product using mice models for testing
-
Bayer's Investigational Riociguat Meets Primary Endpoint In Phase III Study Of Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
10/23/2012
Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent pulmonary hypertension (PH) after surgery.
-
Lilly Diabetes Announces Positive Results Of Phase III Trials Of Dulaglutide In Type 2 Diabetes
10/22/2012
Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes.
-
Hybrigenics Starts Phase II Clinical Trial Of Inecalcitol In Chronic Lymphocytic Leukemia
9/11/2012
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext in Paris, with a focus on research and development of new treatments against proliferative diseases, recently announces the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia (CLL).
-
Cellceutix Plans For European Funded Leukemia Phase 1 Trial
9/10/2012
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs for hard to treat diseases, is pleased to announce that it is in discussions with a major university (the "University") in Europe wishing to conduct clinical trials on Kevetrin™, the Company's flagship anti-cancer compound.
-
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
9/5/2012
Pluristem Therapeutics, Inc. a leading developer of placenta-based cell therapies, announced recently that the Company’s Placental eXpanded (PLX) cells were successfully administered to a third patient at Hadassah Medical Center, following two other life saving compassionate use cases.
-
Autism And Cord Blood Stem Cells: FDA Gives Green Light For Groundbreaking Clinical Trial
8/21/2012
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism.
-
Onyx Pharmaceuticals Initiates Phase 3 Kyprolis™ Head-To-Head Comparison Trial vs. Velcade® In Patients With Relapsed Multiple Myeloma
7/2/2012
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis™ (proposed brand name for carfilzomib) in combination with dexamethasone, versus bortezomib (Velcade®) with dexamethasone in patients with relapsed multiple myeloma.
-
U.S. Clinical Laboratory Testing Sector Revenue To Jump To $63.8B By 2016
6/21/2012
TriMarkPublications.com cites in its newly published "Clinical Laboratory Testing Volume 2: Key Players for Laboratory Testing, Business Trends and Strategies" report that U.S. clinical laboratory testing sector revenue will jump to $63.8 billion by 2016.
-
Phase 3 MISSION Trial Of Nexavar (Sorafenib) In Patients With Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint Of Improving Overall Survival
5/22/2012
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar® (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.